Hans-Ulrich Schildhaus

Dr. Hans-Ulrich Schildhaus

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MIMichaela Angelika Ihle
Michaela Angelika Ihle
JFJana Fassunke
Jana Fassunke
KKKatharina König
Katharina König
IGInga Grünewald
Inga Grünewald
MSMax Schlaak
Max Schlaak
SMSabine Merkelbach-Bruse
Sabine Merkelbach-Bruse
The approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic melanoma. Patients carrying a substitution of valine to glutamic acid at codon 600 (p.V600E) or a substitution of valine to leucine (p.V600K) in BRAF show complete or partial response. Therefore, the precise identification of the underlying somatic mutations is essential. Herein, we evaluate the sensitivity, specificity and feasibility of six different methods for the detection of BRAF mutations.

15 February 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HSHans-Ulrich Schildhaus
Hans-Ulrich Schildhaus
ASAnne M. Schultheis
Anne M. Schultheis
JRJosef Rüschoff
Josef Rüschoff
EBElke Binot
Elke Binot
SMSabine Merkelbach-Bruse
Sabine Merkelbach-Bruse
RBReinhard Buettner
Reinhard Buettner
Purpose: MET is a potential therapeutic target in lung cancer and both MET tyrosine kinase inhibitors and monoclonal antibodies have entered clinical trials. MET signaling can be activated by various mechanisms, including gene amplification. In this study, we aimed to investigate MET amplification status in adeno- and squamous cell carcinomas of the lung. We propose clearly defined amplification scores and provide epidemiologic data on MET amplification in lung cancer. Experimental Design: We evaluated the prevalence of increased MET gene copy numbers in 693 treatment-naïve cancers by FISH, defined clear cutoff criteria, and correlated FISH results to MET IHC. Results: Two thirds (67%) of lung cancers do not have gains in MET gene copy numbers, whereas 3% show a clear-cut high-level amplification (MET/centromer7 ratio ≥2.0 or average gene copy number per nucleus ≥6.0 or ≥10% of tumor cells containing ≥15 MET copies). The remaining cases can be subdivided into intermediate- (6%) and low-level gains (24%). Importantly, MET amplifications occur at equal frequencies in squamous and adenocarcinomas without or with EGFR or KRAS mutations. Conclusion: MET amplification is not a mutually exclusive genetic event in therapy-naïve non–small cell lung cancer. Our data suggest that it might be useful to determine MET amplification (i) before EGFR inhibitor treatment to identify possible primary resistance to anti-EGFR treatment, and (ii) to select cases that harbor KRAS mutations additionally to MET amplification and, thus, may not benefit from MET inhibition. Furthermore, our study provides comprehensive epidemiologic data for upcoming trials with various MET inhibitors. Clin Cancer Res; 21(4); 907–15. ©2014 AACR.

1 February 2014 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
ASAnne M Schultheis
Anne M Schultheis
MBMarc Bos
Marc Bos
KSKatja Schmitz
Katja Schmitz
LWLea Wilsberg
Lea Wilsberg
EBElke Binot
Elke Binot
HSHans-Ulrich Schildhaus
Hans-Ulrich Schildhaus
Small-cell lung cancer (SCLC) comprises about 13–15% of all lung cancers, and more than 29 400 new cases have been diagnosed in the United States in the year 2012. SCLC is a biologically complex tumor typically occurring in heavy smokers. Its medical treatment has almost remained unchanged over the last decades and selected treatment options have not been established so far, mainly due to the lack of targetable genetic alterations. In this study we analyzed a cohort of 307 SCLC samples for fibroblast growth factor receptor 1 (FGFR1) amplification using a dual color FISH probe. FGFR1 status was correlated with clinical data. FGFR1 amplifications were observed in 5.6% of evaluable pulmonary SCLCs. Most of them (93%) fulfilled the criteria for high-level amplification and only one case showed low-level amplification. Amplification patterns were homogenous in the entire tumor area without occurrence of any ‘hot spot’ areas. FGFR1 amplification status was not associated with age, sex, stage, smoking status or overall survival. FGFR1 amplification analysis by FISH analysis in SCLC is, under respect of certain technical issues, applicable in the routine clinical setting. However, the FGFR1 amplification patterns in SCLC differs strongly from the previously described FGFR1 amplification pattern in squamous cell carcinoma of the lung, as positive SCLC harbor mostly homogeneous high-level amplifications. We provide evidence that an estimated number of 1640 newly diagnosed FGFR1-positive SCLC cases in the United States annually could benefit from targeted therapy. Therefore, we recommend including SCLC in the screening for ongoing clinical trials with FGFR1 inhibitors.

26 October 2018 in Der Pathologe
Verified
Journal Article
Closed access
PDF file
HSHans-Ulrich Schildhaus
Hans-Ulrich Schildhaus

1 January 2021 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SGSusanne Grunewald
Susanne Grunewald
LKLillian R. Klug
Lillian R. Klug
TMThomas Mühlenberg
Thomas Mühlenberg
JLJonas Lategahn
Jonas Lategahn
JFJohanna Falkenhorst
Johanna Falkenhorst
SBSebastian Bauer
Sebastian Bauer
Gastrointestinal stromal tumors (GIST) harboring activating mutations of PDGFRA respond to imatinib, with the notable exception of the most common mutation, D842V. Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA-mutant patients treated with avapritinib have developed secondary resistance. Tumor and plasma biopsies in 6 of 7 patients with PDGFRA primary mutations who progressed on avapritinib or imatinib had secondary resistance mutations within PDGFRA exons 13, 14, and 15 that interfere with avapritinib binding. Secondary PDGFRA mutations causing V658A, N659K, Y676C, and G680R substitutions were found in 2 or more patients each, representing recurrent mechanisms of PDGFRA GIST drug resistance. Notably, most PDGFRA-mutant GISTs refractory to avapritinib remain dependent on the PDGFRA oncogenic signal. Inhibitors that target PDGFRA protein stability or inhibition of PDGFRA-dependent signaling pathways may overcome avapritinib resistance. Significance: Here, we provide the first description of avapritinib resistance mechanisms in PDGFRA-mutant GIST. This article is highlighted in the In This Issue feature, p. 1